PSX1001 | PSX1002 | PSX2000 Series | Partners

Prosonix has utilised its unique UMAX^® multi-component particle (MCP^TM) technology to produce novel inhaled combination therapies for treating respiratory diseases - PSX2000 series. This technology enables two or more drug molecules to be combined consistently in a pre-determined ratio in each and every particle in the formulation.

MCP^TM are fully co-associated and have been shown to facilitate co-localisation of active pharmaceutical components at the site of action throughout the lung which in turn offers the potential for enhanced synergistic clinical effect and dose sparing. As a result, Prosonix believes that significant opportunities exist for both new products and life cycle management.

The Company is currently evaluating the potential of MCP^TM containing fluticasone and salmeterol and budesonide and formoterol, the components of GSK's Advair and AstraZeneca's Symbicort, respectively, as well as other combinations of API.

To date, Prosonix has assessed the in vitro delivery of individual components derived from these particles via DPI. In all cases the dose delivered was consistently higher than when using individual micronized powders.